Exploring the role of T cells in Alzheimer's disease, suggests new treatment strategies

Published Date: 10 Mar 2023

Nearly two dozen clinical trials targeting the immune system are in clinical trials for Alzheimer's disease.

Read Full News

Latest News

This Week on NeurologyLive® — December 1, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

NeurologyLive® Brain Games: November 30, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Phosphorylated tau 181!

Early Phase 3 Data Highlight Convenience and Feasibility of Self-Administered Alzheimer Agent Remternetug Marco Meglio

New findings reveal the feasibility of self-administering remternetug, a monoclonal antibody for Alzheimer’s, enhancing treatment options for early-stage patients.

Incorporation of Mini-Mental State Exam Z-Scores May Increase Eligibility for Anti-Amyloid Treatments, Study Suggests Marco Meglio

A Korean study reveals that adjusted MMSE thresholds significantly increase eligibility for anti-amyloid treatments, highlighting demographic disparities and safety concerns.

Expanding Neurology Care in South Miami: Peter Abdelmalik’s Vision Marco Meglio, Peter Abdelmalik, MD

Baptist Health Brain & Spine enhances its neurology leadership with Peter Abdelmalik, MD, focusing on patient care, education, and operational efficiency.

FDA Reverses Course on AMT-130, Citing Insufficient External Data for Submission Marco Meglio

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

Todays Updates

Nalbuphine Extended-Release Reduces Chronic Cough in IPF, with Philip Molyneaux, MBBS Philip Molyneaux, MBBS

New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease Marco Meglio

A phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.

MRI Analysis Shows Stem Cell Therapy Laromestrocel Reduced Neuroinflammation in Mild Alzheimer Disease Isabella Ciccone, MPH

In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.

Phase 3 Trial to Uncover Therapeutic Potential of 5-HT6 Antagonist Masupirdine to Treat Alzheimer Agitation Louie Pasculli

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

Todays Updates

Nalbuphine Extended-Release Reduces Chronic Cough in IPF, with Philip Molyneaux, MBBS Philip Molyneaux, MBBS

New Phase 2 Trial to Test TREM2-Stabilizing Agent VHB937 in Alzheimer Disease Marco Meglio

A phase 2 study at CTAD 2025 explores VHB937's potential in treating early Alzheimer disease, focusing on safety and efficacy in patients.

MRI Analysis Shows Stem Cell Therapy Laromestrocel Reduced Neuroinflammation in Mild Alzheimer Disease Isabella Ciccone, MPH

In an analysis of the phase 2a CLEAR MIND study presented at CTAD 2025, laromestrocel treatment was associated with reduced hippocampal neuroinflammation in patients with mild Alzheimer disease.

Phase 3 Trial to Uncover Therapeutic Potential of 5-HT6 Antagonist Masupirdine to Treat Alzheimer Agitation Louie Pasculli

A new phase 3 clinical trial is underway to evaluate masupirdine, a selective 5-HT6 receptor antagonist, as a potential treatment for agitation in patients with Alzheimer’s disease.

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Pulmonary Rehabilitation Reduces Type 2 Inflammation in High Inflammation Asthma

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

Mental Health Apps Gain High Uptake but Struggle With Adherence, Retention

6 Ophthalmology Headlines You Missed in October 2025

6 Ophthalmology Headlines You Missed in October 2025

Latest News

Here's some of what is coming soon to NeurologyLive® this week.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on Phosphorylated tau 181!

New findings reveal the feasibility of self-administering remternetug, a monoclonal antibody for Alzheimer’s, enhancing treatment options for early-stage patients.

A Korean study reveals that adjusted MMSE thresholds significantly increase eligibility for anti-amyloid treatments, highlighting demographic disparities and safety concerns.

Baptist Health Brain & Spine enhances its neurology leadership with Peter Abdelmalik, MD, focusing on patient care, education, and operational efficiency.

uniQure navigates FDA's unexpected shift on AMT-130, aiming for accelerated approval for Huntington's disease despite recent regulatory challenges.

News All Time

Natalizumab Biosimilar Officially Launched in the United States Marco Meglio

Natalizumab-sztn is an FDA-approved monotherapy for all indications of the reference product natalizumab, including relapsing forms of multiple sclerosis and Crohn disease.

FDA Approves New Intrathecal Administration Route for Spinal Muscular Atrophy Gene Therapy Marco Meglio

The FDA has approved Novartis’ intrathecal formulation of onasemnogene abeparvovec-brve, marketed as Itvisma, for patients ages 2 years and older living with spinal muscular atrophy.

Study Identifies Environmental Risk Factors Significantly Associated With Neuromyelitis Optica Spectrum Disorder Isabella Ciccone, MPH

Findings revealed that vitamin D deficiency was associated with an increased risk of NMOSD in East Asian populations, whereas the effect of smoking among Caucasians and other populations was inconsistent.

Advancing DM1 and DMD Care: Insights on DYNE-101 and DYNE-251 Development Marco Meglio

Doug Kerr, MD, PhD, chief medical officer at Dyne Therapeutics, discusses the clinical development of DYNE-101 for myotonic dystrophy type 1 and DYNE-251 for Duchenne muscular dystrophy.

This Week on NeurologyLive® — November 24, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Positive Phase 3 OCEANIC-STROKE Data Position Asundexian for Upcoming FDA Submission Marco Meglio

Encouraging data from the OCEANIC-STROKE study suggest that asundexian may soon join the therapeutic landscape for secondary stroke prevention as Bayer advances toward submission.

First Patient Dosed in Phase 2 Extension Study of Sabirnetug in Early Alzheimer Disease Louie Pasculli

Acumen Pharmaceuticals initiates a phase 2 trial extension for sabirnetug, targeting early Alzheimer disease and aiming for long-term safety insights.

NeurologyLive® Friday 5 — November 21, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending November 21, 2025.

Case Report Suggests Progressive Brain Atrophy May Occur in NMOSD Without Relapse Marco Meglio

A case report reveals cognitive decline and brain atrophy in a patient with NMOSD, highlighting potential subclinical neurodegeneration despite limited relapses.

Satralizumab Demonstrates Long-term Efficacy and Safety in Patients With NMOSD Louie Pasculli

A recent study confirms satralizumab's long-term safety and efficacy for treating neuromyelitis optica spectrum disorder, supporting its use as a maintenance therapy.

NeurologyLive® Brain Games: November 23, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is neural network plasticity after stroke!

Multi-Arm Phase 2 Trial Fails to Show Efficacy for Cognitive Programs in Treating Long COVID Marco Meglio

A recent trial reveals that online cognitive training and other interventions are ineffective for treating long COVID cognitive symptoms, highlighting treatment challenges.

Reimagining Neuroscience Trials: Precision, Partnership, and Progress Marco Meglio, Daniel Mikol, MD, PhD

Daniel Mikol, MD, PhD, vice president of neuroscience development at AbbVie, discussed how precision tools, AI, and patient partnership are reshaping the design and execution of modern neuroscience clinical trials.

CAR-T Therapy KYV-101 Achieves Durable Response in Phase 2/3 KYSA-6 Trial of Myasthenia Gravis Marco Meglio

KYV-101 shows promising efficacy in treating generalized myasthenia gravis, offering hope for durable remission through innovative CAR T-cell therapy.

Building the Next Era of ALS Clinical Research and Trials Marco Meglio

Ryan Donaghy, MD, an assistant professor of neurology at Northwestern Medicine, discussed the evolving landscape of ALS clinical trials, including advances in biomarkers, genetics, and modern trial design.

Expert Panel Publishes Revised Consensus Recommendations for Diagnosis and Management of NMOSD Isabella Ciccone, MPH

In a newly published study, researchers developed expert-driven, evidence-based, up-to-date consensus recommendations for managing neuromyelitis optica spectrum disorder in Saudi Arabia.

Recommended News For You

Survival is extended by a new treatment option for metastatic colorectal cancer.

"Unusual" Cancers Following Pandemic; Triumph in TNBC; Clinical Trial Interrupted by Shortage.

Merck enhances its oncology pipeline by means of a strategic alliance with Hengrui.

FDA Leaders Explain Their Choice Regarding Cancer Risk Warning in CAR-T Investigation.

In cancer survivors, loneliness is associated with a higher risk of death.

Cancer Patients Who Completed Medication Survey Received More Help From Pharmacists

What Comes After Cancer?

Recommended Articles For You

Modern Oncology Unveiled with Treatment Innovations and Personalized Cancer Care 

Decoding Granular Cell Tumor: What You Need to Know 

Seeing Beyond the Pink Ribbon: AI's New Battle Against Breast Cancer 

The Danger of Rectus Sheath Hematoma: A Hidden Risk of Abdominal Surgery 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Tumor-targeting fluorescent bacteria illuminate cancer for precision surgery

2.

Researchers discover cellular 'doorway' exploited by cancer-causing virus

3.

Pre-operative evaluation of ovarian cancer patients using DWI-MRI is helpful.

4.

Short-course radiation matches standard therapy for endometrial cancer

5.

Fake Cancer Drugs; Let's Talk About Sex; Reducing Cancer-Related Fatigue

1.

Voices That Heal: Redefining Cancer Care Through Patient Insights and Partnership

2.

AI in the War on Cancer: How Digital Tools are Revolutionizing Oncology

3.

From Diagnosis to Recovery: A Comprehensive Guide to Dealing with Cystic Teratoma

4.

The Risk Factors of Venous Thromboembolism and How to Lower Your Chances 

5.

Beyond the Biopsy: The Evolving Landscape of Prostate Cancer Management

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Managing ALK+ NSCLC while Ensuring Long-Term Safety of the Patients

2.

Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part VI

3.

Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part I

4.

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

5.

Key Takeaways from The CROWN Trial For ALK + NSCLC Patients with CNS Diseases


Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot